Allergy Immunotherapy denied as non-formulary by Humana?

Humana's specific coverage criteria for allergy immunotherapy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Allergy Immunotherapy as "Non-Formulary" — and Why You Can Appeal

Allergen immunotherapy is not a standard pharmaceutical product listed on a drug formulary — it is a compounded, patient-specific biological preparation (for subcutaneous immunotherapy) or a specific FDA-approved sublingual tablet (for certain allergens). A "non-formulary" denial usually reflects a formulary classification issue rather than a true coverage exclusion: the allergen extract or the compounding pharmacy may not be on Humana's preferred vendor list, or a sublingual tablet product may not be on the preferred tier. This type of denial is often resolvable through a formulary exception or a medical necessity override.

## Federal Appeal Rights

• ACA Section 2719 external review is available for most plans; approximately four months from denial notice is the standard window.
• ERISA Section 503 (employer plans) entitles you to a written explanation of which specific formulary classification applies and what the exception criteria are.
• Most state insurance codes and ACA regulations require insurers to maintain a formulary exception process — and Humana is required to grant an exception when a non-formulary drug or biological is medically necessary and no formulary alternative is clinically appropriate.
• Expedited review is available when delay endangers health.

## Concrete Appeal Steps and Timeline

1. Obtain the denial letter; identify whether the denial is to a specific product/vendor or to the entire therapeutic class. 2. Ask Humana's pharmacy services team for the formulary exception form — this is a separate, often faster pathway than a standard appeal. 3. If the exception is denied, file a Level 1 internal appeal with medical necessity documentation. 4. In parallel, have your allergist confirm whether any on-formulary alternative could achieve the same clinical outcome — if not, document that explicitly. 5. If upheld internally, file for external review.

## Documentation to Gather

• Prescribing allergist's letter establishing medical necessity and explaining why the specific product or formulation is clinically required and why no on-formulary alternative is adequate for this patient
• Allergy testing records confirming the patient's specific sensitization profile (relevant when the compounded extract is patient-specific)
• Chart documentation of any prior treatment with formulary alternatives and the outcomes or reasons they are not appropriate
• Applicable clinical guideline reference from the relevant allergy/immunology specialty organization supporting the specific product or route

## Criteria-Mapping Structure

Review Humana's formulary exception criteria (available in the plan's pharmacy coverage section). Map each criterion:

| Formulary Exception Criterion | Supporting Documentation | |---|---| | No clinically equivalent formulary alternative available | Allergist letter with clinical explanation | | Medical necessity of the specific non-formulary product | Physician letter + chart | | Diagnosis and sensitization profile specific to the extract | Allergy test results |

Formulary exception requests succeed most often when the prescriber's letter directly addresses each exception criterion and explicitly states that on-formulary alternatives either do not exist (for patient-specific compounded extracts) or are clinically inappropriate for this patient. Request the exception decision in writing within the plan's stated turnaround time.